Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Carcinoma 5Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mouth Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma 3Skin Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Solid Tumors 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1

Interventions

Fulvestrant 2tivozanib 1ribociclib 1palbociclib 1niraparib 1lorlatinib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Imlunestrant 1Cetuximab 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × cemiplimab × 30 days × Clear all
NCT05882734 2026-05-28

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

EMD Serono

Phase 1/2 Active not recruiting
61 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡